Smad4 may help to identify a subset of colorectal cancer patients with early recurrence after curative therapy

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background/Aims: Loss of Smad4 function is associated with the acquisition of advanced colorectal cancer phenotypes. We investigated the role of Smad4 as a prognostic marker after curative therapy. Methodology: Four hundred and twenty nine consecutive colorectal cancers were analyzed by tissue microarray-based immunohistochemical assay. Results: Smad4 protein was expressed in 61.5% (24/39), 53.1% (77/145), 41.3% (78/189) and 34.8% (16/46) of stage I, II, III and IV cancers, respectively. Lymphovascular invasion and lymph node metastasis were strongly correlated with the loss of Smad4 expression (p<0.0001 and p=0.002, respectively). Disease-free survival did not differ between Smad4-positive and Smad4-negative cancers. In stage III disease, time to recurrence after curative therapy was shorter in the Smad4-negative than in the Smad4-positive cancers (20.1±15.1 vs. 34.6±34.1 months, p=0.035). Conclusions: Smad4 protein is of no value in predicting recurrence after curative therapy in colorectal cancer, but it may be helpful in identifying a subset of patients with early recurrence after curative therapy.

Original languageEnglish
Pages (from-to)1933-1936
Number of pages4
JournalHepato-gastroenterology
Volume58
Issue number112
DOIs
StatePublished - 2011 Nov 1

Fingerprint

Colorectal Neoplasms
Smad4 Protein
Recurrence
Neoplasms
Therapeutics
Disease-Free Survival
Lymph Nodes
Neoplasm Metastasis
Phenotype

Keywords

  • Carcinogenesis
  • Colorectal cancer
  • Prognosis
  • Smad4

Cite this

@article{ec764aee477c40c08233dab2b64a37db,
title = "Smad4 may help to identify a subset of colorectal cancer patients with early recurrence after curative therapy",
abstract = "Background/Aims: Loss of Smad4 function is associated with the acquisition of advanced colorectal cancer phenotypes. We investigated the role of Smad4 as a prognostic marker after curative therapy. Methodology: Four hundred and twenty nine consecutive colorectal cancers were analyzed by tissue microarray-based immunohistochemical assay. Results: Smad4 protein was expressed in 61.5{\%} (24/39), 53.1{\%} (77/145), 41.3{\%} (78/189) and 34.8{\%} (16/46) of stage I, II, III and IV cancers, respectively. Lymphovascular invasion and lymph node metastasis were strongly correlated with the loss of Smad4 expression (p<0.0001 and p=0.002, respectively). Disease-free survival did not differ between Smad4-positive and Smad4-negative cancers. In stage III disease, time to recurrence after curative therapy was shorter in the Smad4-negative than in the Smad4-positive cancers (20.1±15.1 vs. 34.6±34.1 months, p=0.035). Conclusions: Smad4 protein is of no value in predicting recurrence after curative therapy in colorectal cancer, but it may be helpful in identifying a subset of patients with early recurrence after curative therapy.",
keywords = "Carcinogenesis, Colorectal cancer, Prognosis, Smad4",
author = "Byungkyu Ahn and Jang, {Si Hyong} and Paik, {Seung Sam} and Lee, {Kang Hong}",
year = "2011",
month = "11",
day = "1",
doi = "10.5754/hge11186",
language = "English",
volume = "58",
pages = "1933--1936",
journal = "Hepato-Gastroenterology",
issn = "0172-6390",
number = "112",

}

Smad4 may help to identify a subset of colorectal cancer patients with early recurrence after curative therapy. / Ahn, Byungkyu; Jang, Si Hyong; Paik, Seung Sam; Lee, Kang Hong.

In: Hepato-gastroenterology, Vol. 58, No. 112, 01.11.2011, p. 1933-1936.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Smad4 may help to identify a subset of colorectal cancer patients with early recurrence after curative therapy

AU - Ahn, Byungkyu

AU - Jang, Si Hyong

AU - Paik, Seung Sam

AU - Lee, Kang Hong

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Background/Aims: Loss of Smad4 function is associated with the acquisition of advanced colorectal cancer phenotypes. We investigated the role of Smad4 as a prognostic marker after curative therapy. Methodology: Four hundred and twenty nine consecutive colorectal cancers were analyzed by tissue microarray-based immunohistochemical assay. Results: Smad4 protein was expressed in 61.5% (24/39), 53.1% (77/145), 41.3% (78/189) and 34.8% (16/46) of stage I, II, III and IV cancers, respectively. Lymphovascular invasion and lymph node metastasis were strongly correlated with the loss of Smad4 expression (p<0.0001 and p=0.002, respectively). Disease-free survival did not differ between Smad4-positive and Smad4-negative cancers. In stage III disease, time to recurrence after curative therapy was shorter in the Smad4-negative than in the Smad4-positive cancers (20.1±15.1 vs. 34.6±34.1 months, p=0.035). Conclusions: Smad4 protein is of no value in predicting recurrence after curative therapy in colorectal cancer, but it may be helpful in identifying a subset of patients with early recurrence after curative therapy.

AB - Background/Aims: Loss of Smad4 function is associated with the acquisition of advanced colorectal cancer phenotypes. We investigated the role of Smad4 as a prognostic marker after curative therapy. Methodology: Four hundred and twenty nine consecutive colorectal cancers were analyzed by tissue microarray-based immunohistochemical assay. Results: Smad4 protein was expressed in 61.5% (24/39), 53.1% (77/145), 41.3% (78/189) and 34.8% (16/46) of stage I, II, III and IV cancers, respectively. Lymphovascular invasion and lymph node metastasis were strongly correlated with the loss of Smad4 expression (p<0.0001 and p=0.002, respectively). Disease-free survival did not differ between Smad4-positive and Smad4-negative cancers. In stage III disease, time to recurrence after curative therapy was shorter in the Smad4-negative than in the Smad4-positive cancers (20.1±15.1 vs. 34.6±34.1 months, p=0.035). Conclusions: Smad4 protein is of no value in predicting recurrence after curative therapy in colorectal cancer, but it may be helpful in identifying a subset of patients with early recurrence after curative therapy.

KW - Carcinogenesis

KW - Colorectal cancer

KW - Prognosis

KW - Smad4

UR - http://www.scopus.com/inward/record.url?scp=84863251477&partnerID=8YFLogxK

U2 - 10.5754/hge11186

DO - 10.5754/hge11186

M3 - Article

C2 - 22024061

AN - SCOPUS:84863251477

VL - 58

SP - 1933

EP - 1936

JO - Hepato-Gastroenterology

JF - Hepato-Gastroenterology

SN - 0172-6390

IS - 112

ER -